Venture
Showing 31–60 of 156 results
-
VentureBridge Biotherapeutics
Bridge Biotherapeutics is a company that focuses on the development of novel drug candidates for areas with unmet medical needs. Their pipeline includes BBT-877 for idiopathic pulmonary fibrosis, BBT-401 for ulcerative colitis, and BBT-176 for non-small cell lung cancer. They are committed to developing high-quality therapeutics for patients worldwide through open innovation.
-
-
VentureCell in Cells
Cell in Cells has a pipeline of organoid regenerative therapies for various diseases, including skin regeneration, cartilage regeneration, and angiogenesis. Its technology can mass-produce uniform organoids with a probability of over 95 percent.
-
VentureCell2in
Cell2in developed a cell quality management system comprising of its proprietary reversible GSH fluorescent probe and a live cell imaging system optimized for this use.
-
VentureCellapeutics
“CELLACON® Platform – the technology of somatic cell reprogramming” is an integrated platform for innovative cell therapy technologies composed of “Cellapeutics Bio’s three major technologies of cella X, cella O, and cella M”.
-
VentureCellatoz Therapeutics
Cellatoz Therapeutics, Inc. is working on the development and commercialization of RMAT (Regenerative Medicine Advanced Therapy) products including mainly cell therapies in order to provide patients suffering from intractable diseases with fundamental treatments of such diseases employing ‘regenerative therapeutic cells’. In addition, they are conducting exploratory researches on chemical inducer screening, gene delivery methods into target cells and so on in order to secure new technologies on therapeutic cells and cell culture methods for future pipelines.
-
VentureCellbiome / Cellbiotech
Cellbiome is a company that focuses on gut microbiome analysis to find personalized gut health management methods. They offer a program called “Microbiome Program” which analyzes your gut microbiome and helps you manage your gut health through healthy lifestyle improvements.
-
VentureCellebrain
CELLeBRAIN is a leading, bio-innovative company developing cutting-edge stem cell-based gene therapy. CELLeBRAIN are dedicated to provide groundbreaking solutions for medical challenges that currently lack effective treatments.
-
VentureCELLID
CELLID is a company that was established in a laboratory at Seoul National University’s College of Pharmacy. They are leading the development of cell-based immune therapeutic vaccines and preventive vaccines for infectious diseases.
-
VentureCellumed Co., Ltd.
-
-
VentureCK Biotech (CK Regeon)
CK Biotech, also known as CK Regeon, is a global biotech startup leading the development of neuroprotective and therapeutic agents against neuronal disorders. They have successfully obtained FDA orphan drug designation for their autism treatment candidate (NV01-A02) and are currently preparing for phase 2 clinical trials in Korea.
-
VentureClinomics
Clinomics is a company that leads the precision medicine for genome-based medical and healthcare. They have developed a CD-Prime platform that helps to detect precise cancer genome variants for early cancer diagnosis and management with a simple blood collection.
-
VentureCT Cells
Leveraging Circulating Tumor Cell (CTC) liquid biopsy technology, CTCELLS leads the industry with its unique automation capabilities, enabling the isolation of all types of circulating tumor cells.
-
VentureCuracle
Curacle is a company that has formed strategic partnerships to help companies integrate high purity exosomes into targeting for greater efficacy, versatility, and results.
-
VentureCURAMYS
Curamys develops “cell & gene therapies for the fundamental cure of rare-intractable disease” and “diagnostic solution of genetic disorder” using the world only & top cell fusion technology.
-
VentureCurigin
Curigin is a company focused on the development of new drugs with a sincere passion for research and development.
-
VentureCurocell
-
VentureCyrus Therapeutics
Cyrus Therapeutics is a company that focuses on the development of ADC cancer drugs. They have the technology to optimize the linker needed for ADC cancer drug development.
-
-
VentureDongbang Medical
Dongbang Medical has strived to produce high-quality medical devices since its establishment in 1985. They export their unique brands in high-quality oriental medical devices, fillers, bio-medical devices, and cosmetics devices to around 50 countries.
-
VentureEHL Bio
-
-
Venture
Ensol Biosciences Inc.
-
VentureEutilex
The core technology that the Eutilex employs for drug development is selecting targets that faithfully enhance or suppress human immune responses. A series of immunomodulatory antibody therapeutics have been developed on that principle to treat cancers and autoimmune diseases.
-
VentureExoCoBio
Exosomes are nano-vesicles between 30 and 150 nm, secreted by cells for intercellular signaling. They contain a variety of physiologically active substances and play key roles in important cellular processes.
-
VentureExosome Plus
Exosome Plus was founded in 2018 to drive an extracellular vesicle (EV) revolution, bringing the best EV isolation and characterization platform in the field of regenerative therapy.
-
VentureEXOSTEMTECH
ExoStemTech’s main pipeline is stem cell-derived exosome therapeutics for various indications including osteoarthritis, liver fibrosis, and lung fibrosis. Especially, Cartisome®, the lead asset to treat osteoarthritis, is about to enter a phase 1 clinical trial as of October 2022.
-
VentureFatiAbGen Co., Ltd.
FatiAbGen is a company that focuses on innovating novel immunotoxin antibody assets and regulating stem cell fate with cutting-edge technologies.
-
VentureFuture Medicine
Future Medicine is a company that develops new drugs that regulate various in vivo targets involving nucleosides. They are working on creating globally innovative drugs for diseases without treatments. Their core research capabilities include a variety of neurological disease models, in vivo and in vitro efficacy assessment systems, and a system for mechanistic studies.